JP2013528563A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528563A5
JP2013528563A5 JP2012544363A JP2012544363A JP2013528563A5 JP 2013528563 A5 JP2013528563 A5 JP 2013528563A5 JP 2012544363 A JP2012544363 A JP 2012544363A JP 2012544363 A JP2012544363 A JP 2012544363A JP 2013528563 A5 JP2013528563 A5 JP 2013528563A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
composition according
retinal
retinopathy
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012544363A
Other languages
English (en)
Japanese (ja)
Other versions
JP5878128B2 (ja
JP2013528563A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2011/059479 external-priority patent/WO2011129461A1/en
Publication of JP2013528563A publication Critical patent/JP2013528563A/ja
Publication of JP2013528563A5 publication Critical patent/JP2013528563A5/ja
Application granted granted Critical
Publication of JP5878128B2 publication Critical patent/JP5878128B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2012544363A 2010-04-12 2011-04-12 網膜疾患を処置するための方法および眼科用組成物 Active JP5878128B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US32334210P 2010-04-12 2010-04-12
US32333810P 2010-04-12 2010-04-12
US61/323,338 2010-04-12
US61/323,342 2010-04-12
US32681110P 2010-04-22 2010-04-22
US61/326,811 2010-04-22
US36294510P 2010-07-09 2010-07-09
US61/362,945 2010-07-09
US40823710P 2010-10-29 2010-10-29
US61/408,237 2010-10-29
PCT/JP2011/059479 WO2011129461A1 (en) 2010-04-12 2011-04-12 Method and ophthalmic composition for treating retinal disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015194346A Division JP2016026182A (ja) 2010-04-12 2015-09-30 網膜疾患を処置するための方法および眼科用組成物

Publications (3)

Publication Number Publication Date
JP2013528563A JP2013528563A (ja) 2013-07-11
JP2013528563A5 true JP2013528563A5 (enExample) 2014-05-29
JP5878128B2 JP5878128B2 (ja) 2016-03-08

Family

ID=44798822

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012544363A Active JP5878128B2 (ja) 2010-04-12 2011-04-12 網膜疾患を処置するための方法および眼科用組成物
JP2012547193A Expired - Fee Related JP5686819B2 (ja) 2010-04-12 2011-04-12 黄斑浮腫を処置するための医薬組成物
JP2015194346A Pending JP2016026182A (ja) 2010-04-12 2015-09-30 網膜疾患を処置するための方法および眼科用組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012547193A Expired - Fee Related JP5686819B2 (ja) 2010-04-12 2011-04-12 黄斑浮腫を処置するための医薬組成物
JP2015194346A Pending JP2016026182A (ja) 2010-04-12 2015-09-30 網膜疾患を処置するための方法および眼科用組成物

Country Status (9)

Country Link
US (2) US20110275715A1 (enExample)
EP (2) EP2558104A4 (enExample)
JP (3) JP5878128B2 (enExample)
KR (2) KR20130099812A (enExample)
CN (2) CN102933217A (enExample)
AR (1) AR080888A1 (enExample)
CA (2) CA2795720A1 (enExample)
TW (2) TW201141486A (enExample)
WO (2) WO2011129461A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600040A (en) * 2009-11-27 2014-03-28 R Tech Ueno Ltd Method for screening an agent being useful for the treatment of dry eye and/or corneal and conjunctival lesion and a pharmaceutical composition obtained by the method.
JP2014510709A (ja) * 2011-04-12 2014-05-01 株式会社アールテック・ウエノ 眼科用水性組成物
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
CN109689042B (zh) * 2016-08-24 2022-07-12 北京生命科学研究所 用于治疗黄斑变性的与恩他卡朋相关的化合物
KR20220004987A (ko) * 2019-04-03 2022-01-12 리젠엑스바이오 인크. 눈 병리에 대한 유전자 요법
EP4094759A1 (en) * 2019-10-30 2022-11-30 Perfuse Therapeutics, Inc. Treatment of ocular diseases using endothelin receptor antagonists
AU2021217358A1 (en) 2020-02-06 2022-09-08 Perfuse Therapeutics, Inc. Compositions for treatment of ocular diseases
IL307997A (en) 2021-04-30 2023-12-01 Perfuse Therapeutics Inc Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
KR20240035513A (ko) 2021-07-09 2024-03-15 알리고스 테라퓨틱스 인코포레이티드 항바이러스 화합물
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396319A1 (en) * 2000-01-18 2001-07-26 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2003020283A2 (en) * 2001-08-29 2003-03-13 Novartis Ag Method for treating diabetic retinopathy
EP2404606A1 (en) * 2003-08-21 2012-01-11 Sucampo AG Ophthalmic compositions comprising a prostaglandin and a viscosity agent
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition

Similar Documents

Publication Publication Date Title
JP2013528563A5 (enExample)
Mayama Calcium channels and their blockers in intraocular pressure and glaucoma
MX385629B (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
JP2008538215A5 (enExample)
PH12013500577B1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
JP2015526467A5 (enExample)
WO2015135306A1 (zh) 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物
RU2012151575A (ru) Нейропротекторное и ретинопротекторное средство n-ацетил-dl-лейцин
MX2019008963A (es) Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico.
RU2012134639A (ru) Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза
Xin et al. Ophthalmic drops with nanoparticles derived from a natural product for treating age-related macular degeneration
FI2765988T3 (fi) Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus
JP2015523986A5 (enExample)
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
HRP20192256T1 (hr) Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta
Day et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension
JP7461667B2 (ja) ナノ低分子ペプチドfh及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用
JP2012505928A5 (enExample)
JP2014521648A5 (enExample)
JP2015027980A5 (enExample)
US20250387410A1 (en) Treatment of anti-vegf refractory ophthalmic retinal eye conditions
CN110496130B (zh) 一种防治糖尿病性视网膜病变的药物组合物
Singh et al. Suprachoroidal Injection of Topotecan for Retinoblastoma: A Preclinical Study
HK1189820A (en) Use of a vegf antagonist to treat angiogenic eye disorders
Novytskvy et al. EFFICACY OF TRABECULAR ABLATION THROUGH THE ANTERIOR CHAMBER ANGLE IN OPEN-ANGLE GLAUCOMA